Metabolic syndrome and non-alcoholic fatty liver disease.

[1]  A. Diehl,et al.  Hepatic triglyceride synthesis and nonalcoholic fatty liver disease , 2008, Current opinion in lipidology.

[2]  R. Rector,et al.  Non-alcoholic fatty liver disease and the metabolic syndrome: an update. , 2008, World journal of gastroenterology.

[3]  S. Mittal.  Clinical Management of the Metabolic Syndrome , 2008 .

[4]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[5]  B. Neuschwander‐Tetri.  Nonalcoholic steatohepatitis and the metabolic syndrome. , 2005, The American journal of the medical sciences.

[6]  G. Marchesini,et al.  Insulin resistance: A metabolic pathway to chronic liver disease , 2005, Hepatology.

[7]  V. Komesidou,et al.  Changes in Liver Histology Accompanying Massive Weight Loss after Gastroplasty for Morbid Obesity , 2005, Obesity surgery.

[8]  L. Sechi,et al.  Plasma adiponectin is decreased in nonalcoholic fatty liver disease. , 2005, European journal of endocrinology.

[9]  D. Befroy,et al.  Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease* , 2004, Journal of Biological Chemistry.

[10]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[11]  J. Manson,et al.  Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. , 2004, JAMA.

[12]  M. Prentki,et al.  AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome , 2004, Nature Reviews Drug Discovery.

[13]  S. Grundy,et al.  Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[14]  S. Grundy,et al.  Clinical Management of Metabolic Syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association Conference on Scientific Issues Related to Management , 2004, Circulation.

[15]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.

[16]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[17]  C. Aguilar-Salinas,et al.  High prevalence of metabolic syndrome in Mexico. , 2004, Archives of medical research.

[18]  R. Unger.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0870 Minireview: Weapons of Lean Body Mass Destruction: The Role of Ectopic Lipids in the Metabolic Syndrome , 2022 .

[19]  M. Prentki,et al.  Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. , 2003, Endocrinology.

[20]  P. Scherer,et al.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0580 Minireview: The Adipocyte—At the Crossroads of Energy Homeostasis, Inflammation, and Atherosclerosis , 2022 .

[21]  Yu Wang,et al.  The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. , 2003, The Journal of clinical investigation.

[22]  G. Reaven,et al.  Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. , 2003, The Journal of clinical endocrinology and metabolism.

[23]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[24]  A. Moser,et al.  Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease , 2003, Hepatology.

[25]  E. Kraegen,et al.  Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. , 2001, Biochemical Society transactions.

[26]  H. Lodish,et al.  Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: Acetyl–CoA carboxylase inhibition and AMP-activated protein kinase activation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[28]  M. Prentki,et al.  Coordinate Regulation of Malonyl-CoA Decarboxylase,sn-Glycerol-3-phosphate Acyltransferase, and Acetyl-CoA Carboxylase by AMP-activated Protein Kinase in Rat Tissues in Response to Exercise* , 2002, The Journal of Biological Chemistry.

[29]  I. Leclercq,et al.  Leptin is essential for the hepatic fibrogenic response to chronic liver injury. , 2002, Journal of hepatology.

[30]  G. Reaven.  Metabolic Syndrome: Pathophysiology and Implications for Management of Cardiovascular Disease , 2002, Circulation.

[31]  N. Weissman,et al.  Stroke Complicating Percutaneous Coronary Interventions: Incidence, Predictors, and Prognostic Implications , 2002, Circulation.

[32]  A. Häkkinen,et al.  Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. , 2002, The Journal of clinical endocrinology and metabolism.

[33]  G. Shulman,et al.  Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β‐cell dysfunction , 2002, European journal of clinical investigation.

[34]  R. Karim,et al.  NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.

[35]  U. Visco-Comandini,et al.  Metformin in non-alcoholic steatohepatitis , 2002, The Lancet.

[36]  J. McGarry.  Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. , 2002, Diabetes.

[37]  R. Unger,et al.  Lipotoxic diseases. , 2002, Annual review of medicine.

[38]  L. Rossetti,et al.  Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. , 2001, The Journal of clinical investigation.

[39]  J. McGarry.  Dysregulation of Fatty Acid Metabolism in the Etiology of Type 2 Diabetes , 2001 .

[40]  M. Toborek,et al.  Fatty acid-mediated activation of vascular endothelial cells. , 2000, Metabolism: clinical and experimental.

[41]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[42]  S. Thung,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Liver Pathology and the Metabolic Syndrome X in , 2022 .

[43]  Demetrios Vavvas,et al.  Malonyl-CoA, fuel sensing, and insulin resistance. , 1999, American journal of physiology. Endocrinology and metabolism.

[44]  C. Fan,et al.  Steatohepatitis, Spontaneous Peroxisome Proliferation and Liver Tumors in Mice Lacking Peroxisomal Fatty Acyl-CoA Oxidase , 1998, The Journal of Biological Chemistry.

[45]  A. Scheen,et al.  Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty , 1998, International Journal of Obesity.

[46]  P. Legmann,et al.  Protein-losing enteropathy secondary to hepatic venous outflow obstruction after liver transplantation. , 1997, Journal of hepatology.

[47]  K. Tanikawa,et al.  Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. , 1997, Journal of hepatology.

[48]  K. Petersen,et al.  Mechanism of free fatty acid-induced insulin resistance in humans. , 1996, The Journal of clinical investigation.

[49]  B. Spiegelman,et al.  IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance , 1996, Science.

[50]  M. Mozzoli,et al.  Effects of fat on insulin-stimulated carbohydrate metabolism in normal men. , 1991, The Journal of clinical investigation.

[51]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.